Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 258

1.

[Musculoskeletal relevance of obesity: a new approach to an old topic].

Tamási L, Miksi Á, Kardos Z, Flórián Á, Szekanecz Z.

Orv Hetil. 2019 Nov;160(44):1727-1734. doi: 10.1556/650.2019.31549. Hungarian.

PMID:
31657254
2.

The effects of breathing exercises in comparison with other exercise programs on cardiorespiratory fitness among healthy female college students.

Csepregi É, Szekanecz Z, Szántó S.

J Sports Med Phys Fitness. 2019 Oct 16. doi: 10.23736/S0022-4707.19.09916-X. [Epub ahead of print]

PMID:
31640315
3.

Biosimilars vs originators: Are they the same?

Sarzi-Puttini P, Marotto D, Caporali R, Galeazzi M, Atzeni F, Hamar A, Soós B, Szekanecz Z.

Autoimmun Rev. 2019 Oct 19:102404. doi: 10.1016/j.autrev.2019.102404. [Epub ahead of print] Review.

PMID:
31639517
4.

A Wide Spectrum of Ocular Manifestations Signify Patients with Systemic Sclerosis.

Szucs G, Szekanecz Z, Aszalos Z, Gesztelyi R, Zsuga J, Szodoray P, Kemeny-Beke A.

Ocul Immunol Inflamm. 2019 Oct 2:1-9. doi: 10.1080/09273948.2019.1657467. [Epub ahead of print]

PMID:
31577461
5.

EULAR points to consider for the development, evaluation and implementation of mobile health applications aiding self-management in people living with rheumatic and musculoskeletal diseases.

Najm A, Nikiphorou E, Kostine M, Richez C, Pauling JD, Finckh A, Ritschl V, Prior Y, Balážová P, Stones S, Szekanecz Z, Iagnocco A, Ramiro S, Sivera F, Dougados M, Carmona L, Burmester G, Wiek D, Gossec L, Berenbaum F.

RMD Open. 2019 Sep 13;5(2):e001014. doi: 10.1136/rmdopen-2019-001014. eCollection 2019.

6.

Assessment of cognitive function in female rheumatoid arthritis patients: associations with cerebrovascular pathology, depression and anxiety.

Oláh C, Kardos Z, Andrejkovics M, Szarka E, Hodosi K, Domján A, Sepsi M, Sas A, Kostyál L, Fazekas K, Flórián Á, Lukács K, Miksi Á, Baráth Z, Kerekes G, Péntek M, Valikovics A, Tamási L, Bereczki D, Szekanecz Z.

Rheumatol Int. 2019 Sep 25. doi: 10.1007/s00296-019-04449-8. [Epub ahead of print]

PMID:
31555886
7.

Effects of 1-year anti-TNF-α therapies on bone mineral density and bone biomarkers in rheumatoid arthritis and ankylosing spondylitis.

Gulyás K, Horváth Á, Végh E, Pusztai A, Szentpétery Á, Pethö Z, Váncsa A, Bodnár N, Csomor P, Hamar A, Bodoki L, Bhattoa HP, Juhász B, Nagy Z, Hodosi K, Karosi T, FitzGerald O, Szücs G, Szekanecz Z, Szamosi S, Szántó S.

Clin Rheumatol. 2019 Sep 14. doi: 10.1007/s10067-019-04771-3. [Epub ahead of print]

PMID:
31522318
8.

Tocilizumab Treatment in Polyarteritis Nodosa.

Bodoki L, Végh E, Szekanecz Z, Szűcs G.

Isr Med Assoc J. 2019 Aug;21(8):560-562. No abstract available.

9.

Long-term efficacy and cost-effectiveness of infliximab as first-line treatment in rheumatoid arthritis: systematic review and meta-analysis.

Zrubka Z, Gulácsi L, Brodszky V, Rencz F, Alten R, Szekanecz Z, Péntek M.

Expert Rev Pharmacoecon Outcomes Res. 2019 Oct;19(5):537-549. doi: 10.1080/14737167.2019.1647104. Epub 2019 Aug 1.

PMID:
31340686
10.

[Autoimmune side effects of immune-checkpoint inhibitor therapies in oncology: pathogenesis, clinic and treatment].

Szekanecz É, Szekanecz Z.

Orv Hetil. 2019 Jun;160(23):887-895. doi: 10.1556/650.2019.31392. Hungarian.

PMID:
31155880
11.

Angiogenesis in Inflammatory Arthritis.

Balogh E, Biniecka M, Fearon U, Veale DJ, Szekanecz Z.

Isr Med Assoc J. 2019 May;5(21):345-352. Review.

12.

Remarkable international variability in reasons for ineligibility and non-participation in the GLORIA trial.

Hartman L, Bos R, Buttgereit F, Güler-Yuksel M, Ionescu R, Kok MR, Lems WF, Micaelo M, Opris-Belinski D, Pusztai A, Santos E, Da Silva J, Szekanecz Z, Zeiner K, Zhang D, Boers M.

Scand J Rheumatol. 2019 Jul;48(4):340-341. doi: 10.1080/03009742.2018.1559880. Epub 2019 May 27. No abstract available.

PMID:
31132016
13.

Gene expression analysis of vascular pathophysiology related to anti-TNF treatment in rheumatoid arthritis.

Póliska S, Besenyei T, Végh E, Hamar A, Pusztai A, Váncsa A, Bodnár N, Szamosi S, Csumita M, Kerekes G, Szabó Z, Nagy Z, Szűcs G, Szántó S, Zahuczky G, Nagy L, Szekanecz Z.

Arthritis Res Ther. 2019 Apr 15;21(1):94. doi: 10.1186/s13075-019-1862-6.

14.
15.

Workforce requirements in rheumatology: a systematic literature review informing the development of a workforce prediction risk of bias tool and the EULAR points to consider.

Unger J, Putrik P, Buttgereit F, Aletaha D, Bianchi G, Bijlsma JWJ, Boonen A, Cikes N, Dias JM, Falzon L, Finckh A, Gossec L, Kvien TK, Matteson EL, Sivera F, Stamm TA, Szekanecz Z, Wiek D, Zink A, Dejaco C, Ramiro S.

RMD Open. 2018 Dec 5;4(2):e000756. doi: 10.1136/rmdopen-2018-000756. eCollection 2018.

16.

EULAR 'points to consider' for the conduction of workforce requirement studies in rheumatology.

Dejaco C, Putrik P, Unger J, Aletaha D, Bianchi G, Bijlsma JW, Boonen A, Cikes N, Finckh A, Gossec L, Kvien TK, Madruga Dias J, Matteson EL, Sivera F, Stamm TA, Szekanecz Z, Wiek D, Zink A, Ramiro S, Buttgereit F.

RMD Open. 2018 Dec 5;4(2):e000780. doi: 10.1136/rmdopen-2018-000780. eCollection 2018.

17.

The NLRP3 inflammasome - interleukin 1 pathway as a therapeutic target in gout.

Szekanecz Z, Szamosi S, Kovács GE, Kocsis E, Benkő S.

Arch Biochem Biophys. 2019 Jul 30;670:82-93. doi: 10.1016/j.abb.2019.01.031. Epub 2019 Jan 30. Review.

PMID:
30710503
18.

Peripheral Lymphocyte Multidrug Resistance Activity as a Predictive Tool of Biological Therapeutic Response in Rheumatoid Arthritis.

Toldi G, Batel P, Baráth S, Szerémy P, Apjok A, Filkor K, Szántó S, Szűcs G, Szamosi S, Häupl T, Grützkau A, Szekanecz Z.

J Rheumatol. 2019 Jun;46(6):572-578. doi: 10.3899/jrheum.180793. Epub 2019 Feb 1.

PMID:
30709954
19.

Long-Term Efficacy of Tumor Necrosis Factor Inhibitors for the Treatment of Methotrexate-Naïve Rheumatoid Arthritis: Systematic Literature Review and Meta-Analysis.

Gulácsi L, Zrubka Z, Brodszky V, Rencz F, Alten R, Szekanecz Z, Péntek M.

Adv Ther. 2019 Mar;36(3):721-745. doi: 10.1007/s12325-018-0869-8. Epub 2019 Jan 12.

PMID:
30637590
20.

Common mechanisms and holistic care in atherosclerosis and osteoporosis.

Szekanecz Z, Raterman HG, Pethő Z, Lems WF.

Arthritis Res Ther. 2019 Jan 10;21(1):15. doi: 10.1186/s13075-018-1805-7. Review.

21.

Autoimmune and angiogenic biomarkers in autoimmune atherosclerosis.

Balogh E, Pusztai A, Hamar A, Végh E, Szamosi S, Kerekes G, McCormick J, Biniecka M, Szántó S, Szűcs G, Nagy Z, Fearon U, Veale DJ, Szekanecz Z.

Clin Immunol. 2019 Feb;199:47-51. doi: 10.1016/j.clim.2018.12.011. Epub 2018 Dec 10.

PMID:
30543922
22.

[Recent advances in gout: pathogenesis, diagnosis, comorbidities, treatment].

Soós B, Szamosi S, Benkő S, Paragh G, Szekanecz Z.

Orv Hetil. 2018 Oct;159(40):1625-1636. doi: 10.1556/650.2018.31270. Review. Hungarian.

PMID:
30277413
23.

Characteristics of difficult-to-treat rheumatoid arthritis: results of an international survey.

Roodenrijs NMT, de Hair MJH, van der Goes MC, Jacobs JWG, Welsing PMJ, van der Heijde D, Aletaha D, Dougados M, Hyrich KL, McInnes IB, Mueller-Ladner U, Senolt L, Szekanecz Z, van Laar JM, Nagy G; whole EULAR Task Force on development of EULAR recommendations for the comprehensive management of difficult-to-treat rheumatoid arthritis.

Ann Rheum Dis. 2018 Dec;77(12):1705-1709. doi: 10.1136/annrheumdis-2018-213687. Epub 2018 Sep 7.

PMID:
30194273
24.

2018 update of the EULAR recommendations for the management of hand osteoarthritis.

Kloppenburg M, Kroon FP, Blanco FJ, Doherty M, Dziedzic KS, Greibrokk E, Haugen IK, Herrero-Beaumont G, Jonsson H, Kjeken I, Maheu E, Ramonda R, Ritt MJ, Smeets W, Smolen JS, Stamm TA, Szekanecz Z, Wittoek R, Carmona L.

Ann Rheum Dis. 2019 Jan;78(1):16-24. doi: 10.1136/annrheumdis-2018-213826. Epub 2018 Aug 28.

PMID:
30154087
25.

Editorial: Comorbidity Burden in Rheumatic Diseases.

Nikiphorou E, Nurmohamed MT, Szekanecz Z.

Front Med (Lausanne). 2018 Jul 3;5:197. doi: 10.3389/fmed.2018.00197. eCollection 2018. No abstract available.

26.

Corneal Manifestations of Systemic Sclerosis.

Nagy A, Rentka A, Nemeth G, Ziad H, Szücs G, Szekanecz Z, Gesztelyi R, Zsuga J, Aszalos Z, Szodoray P, Kemeny-Beke A.

Ocul Immunol Inflamm. 2019;27(6):968-977. doi: 10.1080/09273948.2018.1489556. Epub 2018 Jul 17.

PMID:
30015530
27.

Impact of obesity on autoimmune arthritis and its cardiovascular complications.

Van Raemdonck K, Umar S, Szekanecz Z, Zomorrodi RK, Shahrara S.

Autoimmun Rev. 2018 Aug;17(8):821-835. doi: 10.1016/j.autrev.2018.02.007. Epub 2018 Jun 6. Review.

PMID:
29885537
28.

Oxidative stress impairs energy metabolism in primary cells and synovial tissue of patients with rheumatoid arthritis.

Balogh E, Veale DJ, McGarry T, Orr C, Szekanecz Z, Ng CT, Fearon U, Biniecka M.

Arthritis Res Ther. 2018 May 29;20(1):95. doi: 10.1186/s13075-018-1592-1.

29.

Microthrombotic renal involvement in an SLE patient with concomitant catastrophic antiphospholipid syndrome: the beneficial effect of rituximab treatment.

Diószegi Á, Tarr T, Nagy-Vincze M, Nánásy-Vass M, Veisz R, Bidiga L, Dezső B, Balla J, Szodoray P, Szekanecz Z, Soltész P.

Lupus. 2018 Aug;27(9):1552-1558. doi: 10.1177/0961203318768890. Epub 2018 Apr 10.

PMID:
29635999
30.

The Impact of Drug Metabolism Gene Polymorphisms on Therapeutic Response and Survival in Diffuse Large B-Cell Lymphoma Patients.

Pál I, Illés Á, Gergely L, Pál T, Radnay Z, Szekanecz Z, Zilahi E, Váróczy L.

Isr Med Assoc J. 2018 Apr;20(4):217-221.

31.

Laser-induced plasma spectroscopy (LIPS): use of a geological tool in assessing bone mineral content.

Andrássy L, Gomez I, Horváth Á, Gulyás K, Pethö Z, Juhász B, Bhattoa HP, Szekanecz Z.

Lasers Med Sci. 2018 Aug;33(6):1225-1236. doi: 10.1007/s10103-018-2462-4. Epub 2018 Feb 17.

PMID:
29453616
32.

Increased frequency of temporal acoustic window failure in rheumatoid arthritis: a manifestation of altered bone metabolism?

Kardos Z, Oláh C, Sepsi M, Sas A, Kostyál L, Bóta T, Bhattoa HP, Hodosi K, Kerekes G, Tamási L, Bereczki D, Szekanecz Z.

Clin Rheumatol. 2018 May;37(5):1183-1188. doi: 10.1007/s10067-018-4003-8. Epub 2018 Jan 30.

PMID:
29383454
33.

Posterior Reversible Encephalopathy Syndrome (PRES) Associated with Thrombotic Thrombocytopenic Purpura in a Systemic Lupus Erythematosus Patient.

Szamosi S, Bodnár N, Brugós B, Hortobágyi T, Méhes G, Szabó Z, Végh E, Horváth Á, Szekanecz Z, Szűcs A, Szűcs G.

Isr Med Assoc J. 2017 Nov;19(11):700-702. No abstract available.

34.

Effect of Fcγ-receptor 3a (FCGR3A) gene polymorphisms on rituximab therapy in Hungarian patients with rheumatoid arthritis.

Pál I, Szamosi S, Hodosi K, Szekanecz Z, Váróczy L.

RMD Open. 2017 Nov 1;3(2):e000485. doi: 10.1136/rmdopen-2017-000485. eCollection 2017.

35.

Targeting Cannabinoid Signaling in the Immune System: "High"-ly Exciting Questions, Possibilities, and Challenges.

Oláh A, Szekanecz Z, Bíró T.

Front Immunol. 2017 Nov 10;8:1487. doi: 10.3389/fimmu.2017.01487. eCollection 2017. Review.

36.

Pneumococcal vaccination in autoimmune rheumatic diseases.

Rákóczi É, Szekanecz Z.

RMD Open. 2017 Sep 14;3(2):e000484. doi: 10.1136/rmdopen-2017-000484. eCollection 2017. Review.

37.

Assessment of intracranial vessels in association with carotid atherosclerosis and brain vascular lesions in rheumatoid arthritis.

Oláh C, Kardos Z, Sepsi M, Sas A, Kostyál L, Bhattoa HP, Hodosi K, Kerekes G, Tamási L, Valikovics A, Bereczki D, Szekanecz Z.

Arthritis Res Ther. 2017 Sep 26;19(1):213. doi: 10.1186/s13075-017-1422-x.

38.

[Why would doctors from Debrecen go abroad? Results of a questionnaire].

Szekanecz Z, Tóth Z, Hamar A, Lánczi L.

Orv Hetil. 2017 Sep;158(37):1458-1468. doi: 10.1556/650.2017.30842. Hungarian.

PMID:
28891705
39.

Association between objective signs and subjective symptoms of dry eye disease in patients with systemic sclerosis.

Rentka A, Nagy A, Harsfalvi J, Szucs G, Szekanecz Z, Gesztelyi R, Szodoray P, Kemeny-Beke A.

Rheumatol Int. 2017 Nov;37(11):1835-1845. doi: 10.1007/s00296-017-3794-2. Epub 2017 Sep 7.

PMID:
28884335
40.

Opportunities and challenges in rheumatology research in Central Europe.

Szekanecz Z, Anic B, Héjj G, Holc I, Hunka A, Kucharz E, Machold K, Mayer M, Pahor A, Puchner R, Rovensky J, Senolt L, Tuchynova A, Vencovsky J, Smolen JS.

Arthritis Res Ther. 2017 Sep 4;19(1):196. doi: 10.1186/s13075-017-1368-z.

41.

[Vitamin D metabolism and osteoporosis in systemic sclerosis].

Szamosi S, Horváth Á, Szekanecz Z, Szűcs G.

Orv Hetil. 2017 Aug;158(32):1252-1258. doi: 10.1556/650.2017.30816. Review. Hungarian.

PMID:
28780880
42.

Antigen-specific immunotherapies in rheumatic diseases.

Pozsgay J, Szekanecz Z, Sármay G.

Nat Rev Rheumatol. 2017 Sep;13(9):525-537. doi: 10.1038/nrrheum.2017.107. Epub 2017 Jul 13. Review.

PMID:
28701761
43.

[Experience with a rheumatoid arthritis biobank: analysis of biological samples and clinical data of 204 patients].

Pál I, Pusztai A, Csomor P, Szekanecz Z.

Orv Hetil. 2017 Feb;158(7):270-277. doi: 10.1556/650.2017.30650. Hungarian.

PMID:
28462625
44.

Determinants of biological drug survival in rheumatoid arthritis: evidence from a Hungarian rheumatology center over 8 years of retrospective data.

Brodszky V, Bíró A, Szekanecz Z, Soós B, Baji P, Rencz F, Tóthfalusi L, Gulácsi L, Péntek M.

Clinicoecon Outcomes Res. 2017 Feb 15;9:139-147. doi: 10.2147/CEOR.S124381. eCollection 2017.

45.

Evaluation of commonly used tear sampling methods and their relevance in subsequent biochemical analysis.

Rentka A, Koroskenyi K, Harsfalvi J, Szekanecz Z, Szucs G, Szodoray P, Kemeny-Beke A.

Ann Clin Biochem. 2017 Sep;54(5):521-529. doi: 10.1177/0004563217695843. Epub 2017 Jun 28. Review.

PMID:
28193107
46.

Effects of targeted therapies on the bone in arthritides.

Szentpétery Á, Horváth Á, Gulyás K, Pethö Z, Bhattoa HP, Szántó S, Szücs G, FitzGerald O, Schett G, Szekanecz Z.

Autoimmun Rev. 2017 Mar;16(3):313-320. doi: 10.1016/j.autrev.2017.01.014. Epub 2017 Jan 31. Review.

PMID:
28159704
47.

TLRs, future potential therapeutic targets for RA.

Elshabrawy HA, Essani AE, Szekanecz Z, Fox DA, Shahrara S.

Autoimmun Rev. 2017 Feb;16(2):103-113. doi: 10.1016/j.autrev.2016.12.003. Epub 2016 Dec 15. Review.

48.

2016 update of the EULAR recommendations for the management of early arthritis.

Combe B, Landewe R, Daien CI, Hua C, Aletaha D, Álvaro-Gracia JM, Bakkers M, Brodin N, Burmester GR, Codreanu C, Conway R, Dougados M, Emery P, Ferraccioli G, Fonseca J, Raza K, Silva-Fernández L, Smolen JS, Skingle D, Szekanecz Z, Kvien TK, van der Helm-van Mil A, van Vollenhoven R.

Ann Rheum Dis. 2017 Jun;76(6):948-959. doi: 10.1136/annrheumdis-2016-210602. Epub 2016 Dec 15.

49.

Comparison of peripheral quantitative computed tomography forearm bone density versus DXA in rheumatoid arthritis patients and controls.

Juhász B, Gulyás K, Horváth Á, Pethő Z, Bhattoa HP, Váncsa A, Szekanecz É, Horváth C, Kocsis J, Horváth Z, Hodosi K, Szántó S, Szűcs G, Szekanecz Z.

Osteoporos Int. 2017 Apr;28(4):1271-1277. doi: 10.1007/s00198-016-3850-x. Epub 2016 Dec 10.

PMID:
27942777
50.

EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update.

Agca R, Heslinga SC, Rollefstad S, Heslinga M, McInnes IB, Peters MJ, Kvien TK, Dougados M, Radner H, Atzeni F, Primdahl J, Södergren A, Wallberg Jonsson S, van Rompay J, Zabalan C, Pedersen TR, Jacobsson L, de Vlam K, Gonzalez-Gay MA, Semb AG, Kitas GD, Smulders YM, Szekanecz Z, Sattar N, Symmons DP, Nurmohamed MT.

Ann Rheum Dis. 2017 Jan;76(1):17-28. doi: 10.1136/annrheumdis-2016-209775. Epub 2016 Oct 3. Review.

PMID:
27697765

Supplemental Content

Loading ...
Support Center